Beamtree Holdings Ltd · ASX:BMT
Beamtree — H1 FY2021 Earnings Presentation
30 slides from Beamtree's earnings presentation, Aug 27, 2021
Slide 1: A strategy for growth and Half Year results
rsonal use only Better has no limit A strategy for growth and Half Year results
Slide 2: Leadership: Introducing Tim Kelsey as CEO
Leadership: Introducing Tim Kelsey as CEO rsonal use only “Our vision is to accelerate growth by integrating PKS services into a platform that offers best in class information and knowledge management in global healthcare.” • International leader in digital health and former CEO of Australian Digita
Slide 3: PKS capital structure and share price
PKS capital structure and share price rsonal use only Key executives and directors of PKS are material equity holders ensuring strong alignment with all shareholders Broad ownership with an aligned Board & Management Strong 12 month share price performance 0.45 4.5 0.40 4.0 17% 0.35 3.5 29% 0.30 3.0
Slide 4: Who we are and what we do
Who we are and what we do rsonal use only “Intelligent systems for better health outcomes” Pressures on Healthcare Organisations PKS products and services have a broad range of applications across the healthcare industry: Financial Pressures • Improve the accuracy and timeliness of health data colle
Slide 5: What problems are we solving?
What problems are we solving? rsonal use only Better information is better healthcare… Quality Viability Sustainability Regulators and payors require Errors and waste account for COVID-19 exposed vital gaps transparency of quality and 15-30% of health spend in management information patient outcomes
Slide 6: Our products support health services
Our products support health services make the best decisions rsonal use only Data Insight Action Data Clinical Quality High value Evidence-based Quality & Safety healthcare decisions RippleDown® Classifying Auditing the Benchmarking best Real-time clinical clinical data quality of clinical practice
Slide 7: Achieving tangible outcomes…
Achieving tangible outcomes… rsonal use only “RippleDown really enhances our service. We are “The PKS solutions implemented by us have driven now able to deliver a highly customised service to many improvements in health information, data GPs with better quality information that they use management
Slide 8: …with a global footprint
…with a global footprint PKS has reinforced its Australian client base and expanded into Ireland, Singapore and the Middle East rsonal use only Partner A Europe USA Middle East Asia Australia South Africa NZ Copyright © PKS Holdings Limited – All Rights Reserved [Commercial-in-Confidence]
Slide 9: Three pillars of growth to build a $50m ARR business…
Three pillars of growth to build a $50m ARR business… “PKS has a unique opportunity to transform information and knowledge management building on our trusted global credentials in rsonal use only data quality, clinical informatics and the automation of human expertise.” Tim Kelsey – CEO PKS is an in
Slide 10: The three pillars of growth
The three pillars of growth rsonal use only 1 1. Channel: accelerate and advance new and existing channel partner relationships. Scale the Core 2. International penetration: leverage recent wins, expand Europe, Middle East to define our direct channel in these markets. 3. New functionality: PICQ, Qc
Slide 11: The three pillars of growth
The three pillars of growth rsonal use only 2 1. New Value & Outcomes Dashboard: providing near real time comparative data on Leverage outcomes and financial efficiency. the Core 2. Data Analytics & Visualisation: data rich environment offers point-in-time display of hospital and pathology workflow.
Slide 12: The three pillars of growth
The three pillars of growth rsonal use only 3 1. New automated coding technology: reduces cost of clinical record administration Expand and enable real-time data analytics and clinical decision support the Core 2. New platforms: provides enterprise knowledge management service in aged, primary and c
Slide 13: Delivering a $50m ARR outcome
Delivering a $50m ARR outcome rsonal use only Accelerating 1 2 3 growth across Scale the Core Leverage the Core Expand the Core Domestic TAM Scale Core Public three horizons Domestic $100m, TAM Leverage Core Domestic $210m, TAM Expand Core $m market size Domestic $117m Private International $3.8bn I
Slide 14: Built on world-class science and technology
Built on world-class science and technology rsonal use only A next-generation user Ground-breaking innovation in the experience for interacting with application of mathematics, data statistical health information, analytics, expert systems & coupled with clinical intervention knowledge engineering t
Slide 15: Empowering learning health systems
Empowering learning health systems rsonal use only Continuous improvement driven by health information Support clinicians Encode in during intervention standard formats Develop intelligent Monitor for quality rules Mathematical and statistical analysis Copyright © PKS Holdings Limited – All Rights R
Slide 16: End Game: Quality, reliable, real time knowledge
End Game: Quality, reliable, real time knowledge rsonal use only Common data standards Shared analytic insights Shared expertise Copyright © PKS Holdings Limited – All Rights Reserved [Commercial-in-Confidence]
Slide 17: 1H FY2021 Financials
rsonal use only 1H FY2021 Financials
Slide 18: 1H FY21 Highlights
1H FY21 Highlights “PKS has performed well in the first half of the year. Recurring revenues are ahead of rsonal use only expectations – confirming the importance of our services in global healthcare as it faces the unprecedented pressures of COVID. We continue to empower improved health outcomes th
Slide 19: 1H FY21 Operational Highlights
1H FY21 Operational Highlights • PKS’ subsidiary, Pavilion Health, signed a strategic Software License renewal agreement with rsonal use only Healthscope for its RISQ™ product in July 2020 Healthscope module expansion • Pavilion Health also signed a renewal agreement with Healthscope in September 20
Slide 20: 1H FY21 Revenue Breakdown
1H FY21 Revenue Breakdown rsonal use only PKS is focused on increasing direct revenue and expanding its global customer base Direct Vs Indirect Revenue Revenue by geography Revenue Highlights • Recurring Revenue of 88% 11% 23% • Growth in Recurring Revenue of 21% • Broad revenue spread with 10% grow
Slide 21: 1H FY21 Group Financial Comparison
1H FY21 Group Financial Comparison rsonal use only 1H FY21 Profit & Loss 1H FY21 Commentary $(,000) 1H FY21 1H FY20 Pro-forma • Recurring revenue represented 88% of total revenue in 1H 2021, up from 74% in 1H FY2020 on a pro-forma basis Subscription, License & Usage Revenue - recurring 3,058 2,500 S
Slide 22: 1H FY21 Group Cash Flow
1H FY21 Group Cash Flow rsonal use only 1H FY21 Cash Flow 1H FY21 Commentary ($’000) 1H FY21 1H FY20 • PKS continues to retain a strong cash balance of $3.4 million with zero Receipts from customers (inclusive of GST) 3,541 2,114 debt Payments to suppliers and employees (inclusive of GST) (3,656) (1
Slide 23: Board of Directors
Board of Directors rsonal use only Mike Hill Ron van der Pluijm Andrew Gray Paul Williams Stephen Borness Brad Lancken Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Chris Smith Director Director CEO ▪ Former
Slide 24: Capital raising overview
rsonal use only Capital raising overview
Slide 25: Overview
Overview rsonal use only Description Details Description Details • $12.0m Placement to professional and Existing Shares on Issue 187,518,543 sophisticated investors under s.708 (8) and (11) of the Corporations Act 2001 (Cth) Existing Options & Consideration Rights on Issue 24,450,000 Offer Structure
Slide 26: Indicative Timetable
Indicative Timetable rsonal use only Description Date (2021) Trading Halt 9am Friday, 19 February Bookbuild conducted for the Placement Friday, 19 February – Monday, 22 February Record Date for SPP Monday, 22 February Announcement of Placement and SPP Tuesday, 23 February SPP Offer opens Friday, 26
Slide 27: Use of Funds
Use of Funds rsonal use only Source of Funds Max. Use of Funds Max. (A$m) (A$m) Capital Raising 12.0 Research & Product Development 5.0 Sales & Marketing 2.0 Data Science & Clinical Informatics 2.0 Automated Coding 2.5 Costs of the Offer 0.5 Total 12.0 Total 12.0 1. Does not include the gross procee
Slide 28: Post Offer Pro-Forma Balance Sheet
Post Offer Pro-Forma Balance Sheet rsonal use only Balance Sheet ($) 31-Dec-20 Impact of the Offer Pro Forma 31 December 2020 Assets Current assets 4,871,788 12,000,000 16,871,788 Non-current assets 27,317,609 - 27,317,609 Total assets 32,189,397 12,000,000 44,189,397 Liabilities Current liabilities
Slide 29: For further information
rsonal use only For further information Tim Kelsey Mike Hill CEO PKS Holdings Chairman PKS Holdings Phone: 0476 835 311 Phone: 0421 056 691
Slide 30: Important notice and disclaimer
Important notice and disclaimer rsonal use only The material in this presentation is general background information about PKS Holdings Limited (PKS) and is current at the date of the presentation, 17 February 2021. This presentation may contain statements that are, or may be deemed to be, forward lo